Drug Profile
Research programme: nucleoside reverse transcriptase inhibitors - Bristol-Myers Squibb/Pharmasset
Latest Information Update: 17 Jan 2008
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb; Pharmasset
- Class Nucleosides
- Mechanism of Action RNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis B; HIV infections
Most Recent Events
- 09 Oct 2001 DuPont Pharmaceuticals has been acquired by Bristol-Myers Squibb
- 12 Jul 2000 Preclinical development for Hepatitis B in USA (Unknown route)
- 12 Jul 2000 Preclinical development for HIV infections treatment in USA (Unknown route)